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Conference on Comparative
Metabolism and Toxicity of Vinyl
Chloride-Related Compounds:
Overview and Summary
by Sheldon D. Murphy*t
I suspect that there is little more that can be
said about the metabolism and toxicity of haloge-
nated olefins that has not been said at this meeting.
Although I have faithfully attended and taken notes
on all papers presented here, it would be foolhardy
for me to attempt to make either complimentary or
critical comments about each and every paper.
In the first session ofthis conference we learned
of factors that influence the tumorogenicity, dem-
onstrated experimentally, not only with the now-
infamous vinyl chloride, but also with vinylidene
chloride, hexachlorocyclobutadiene, trichloro-
ethylene, and several other related compounds
tested in the National Cancer Institute's carcinogen
screening program. Clearly, it would seem, the
halogenated olefin class of compounds will be con-
sidered presumptive carcinogens. Are there ways
to predict, short of long-term animal testing,
whether or not a particular halogenated olefin rep-
resents a carcinogenic hazard? Papers by Drs.
Henschler, Hathaway, Van Duuren, Leibman, and
Van Dyke dealt with biological activity as a func-
tion ofchemical and physical-chemical characteris-
tics ofcompounds. Consideration ofthese relation-
ships coupled with metabolic considerations may
provide testable theoretical proposals for predicting
the mutagenic and carcinogenic potential ofhaloge-
nated aliphatic and olefinic compounds. Papers by
Dr. Rosenkrantz and others suggest the usefulness
ofcertain in vitro test systems forfurther evaluating
mutagenic and carcinogenic potential.
*Harvard University, School of Public Health, Boston, Mas-
sachusetts 02115.
tPresent address: Division of Toxicology, Department of
Pharmacology, University ofTexas Medical School atHouston,
P. 0. Box 20708, Houston, Texas 77025.
Exciting as these possibilities are, several reports
at this conference have raised the question as to
whether some of the conventional indices of
hepato- and nephrotoxicity produced by the
halogenated olefins do not also have predictive
value. That is, would detection of injury by these
indices suffice to indicate the need to prevent ex-
posures which might, at higher doses or longer
times, be carcinogenic? Ofcourse, this possibility is
only practical if there is assurance that the surveil-
lance of the health ofworkers or others who might
be exposed to these compounds is adequate to de-
tect the early and reversible indices of injury and
that such detection leads to correction of the ex-
posure conditions that resulted in early injury. I
seriously doubt whether we have a sufficient data
base on dose-response and time-response relation-
ships for reversible chemical injury and irreversible
events (as carcinogenesis) to adopt such an ap-
proach. However, the acquisition of data that may
permit evaluation of such possibilities is an obvious
area for research and should guide hypothesis for-
mulations and experimental design.
We heard frequent mention of pharmacokinetic
considerations as determinants of the toxic re-
sponses to halogenated olefins. Are the concepts of
saturable metabolic pathways and rate-limiting ac-
tivation and detoxication reactions sufficiently de-
veloped to allow us to decide whether or not effects
seen in high-dose acute studies have implications
for chronic low-dose exposures? Certainly there
seems to be hope in this approach, an approach
which may even allow monitoring ofurinary excre-
tion of metabolites in exposed workers as a means
of determining their susceptibility to injury. How-
ever, the practical realization of such potential de-
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important in producing either more or less toxic or
carcinogenic metabolites. Indeed, we may be able
to account for as much as 95% of a compound's
metabolism, but, if an unidentified metabolite
which represents only 1% of the total is the active
compound, it will be difficult to convincingly argue
that we can evaluate hazard by pharmacokinetic
considerations. Nevertheless, the coupling of dis-
tribution pharmacokinetics with enzymatic bio-
transformation kinetics, or with specific target-
molecule reaction kinetics, is the only logical means
of attempting to move from empirical considera-
tions in safety evaluation to scientific predictive
models.
On the topic ofmultiple pathways ofmetabolism,
the demonstration that the hepatotoxic action of
halothane is enhanced under hypoxic conditions
adds a new aspect to our considerations of the
metabolism-toxicity relationship for this com-
pound. The report and suggestion that a reductive
pathway of metabolism may ultimately provide the
toxic, reactive metabolite of halothane illustrates
that we must not fall into the trap of thinking that
microsomal oxidases are the only critical pathways
for activation ofthese compounds. Indeed, four dec-
ades ago, it was the enzymatic reduction of pron-
tosil that was one of the first demonstrations of
metabolic formation of a more biologically active
derivative of an otherwise inactive drug.
Some evidence was presented at this conference
that indicates that the low-frequency occurrence of
acute hepatotoxicity in humans exposed to
halothane and related anesthetics is not, as once
thought, a case of allergic response, but may in-
stead be metabolically based. A logical question
might be: What genetic or environmental factors
contribute to this metabolic uniqueness?
The demonstration, by Dr. Rosenkrantz, of in
vitro mutagenicity of urine samples from anes-
thesiology staff is, of course, a provocative obser-
vation in view ofthe apparent association ofexcess
incidence ofcancer in these hospital personnel. The
possible application ofin vitro screening methods to
detection of presumptive carcinogens in human
body fluids will most certainly force the issue of
research to corroborate or refute the validity of
these tests in the total hazard evaluation process.
Perhaps the cytogenetic studies of the type de-
scribed for vinyl chloride workers by Dr. Purchase
will be a part ofthis evaluation.
We have heard much about covalent binding of
halo-olefins and their metabolites. Indeed,
nonspecific covalent binding to proteins has served
well as a means of detecting the formation of more
reactive metabolites. However, we have really little
information regarding what percentage ofthis bind-
ing, if any, is to critical biological macromolecules.
Several papers pointed out the need to separate
nonspecific and noncritical binding from critical
target site binding, e.g., to nucleic acids or phos-
pholipids. Similarly, it is obvious that glutathione is
an important endogenous modulator of halo-olefin
toxicity, at least in part because it provides a con-
jugating molecule for detoxification. It has been
suggested that glutathione may act in other ways to
protect reactive SH sites in membranes which may
be critical target sites.
In short, we seem to have some ideas, but rela-
tively little convincing demonstration of specific
target sites, to explain the acute or chronic, non-
tumorigenic, toxicity of the halo-olefins. Or does it
have to be halo-olefins? Witness Rory Conolly's
observation of hepatotoxicity of ethylene in PCB-
induced rats.
And what of interactions? Both the tumorigenic-
ity and other cytotoxic or organ toxicity of halo-
olefins have been reported at this conference to be
modified by numerous factors: both endogenous,
e.g. species, age, sex; and exogenous, e.g. diet,
other chemicals, ethanol ingestion. How can these
influences be predicted or how should they be taken
into account in hazard evaluations? I suspect that
the answer to that question will come only when we
have a more thorough understanding of the
mechanisms by which these interactions occur. At-
tempts to explain interactions have dealt previously
with attempting to manipulate the epoxide hydrase
metabolism system and the glutathione transferase
system. Certainly epoxide formation seems to be a
central and critical intermediate in the biological ac-
tivation of most (if not all) of the halo-olefins.
Whether or not the use of inducers or inhibitors of
epoxidation and of epoxide hydration will provide
insight into mechanisms of toxic interactions of
halo-olefins will likely be a subject of continuing
investigation in a number oflaboratories.
Finally, I think this conference demonstrates that
in the last five years-since Dr. Viola's and Dr.
Maltoni's first reports oftumorigenic action ofvinyl
chloride-we have come quite a distance in under-
standing the comparative toxicity and metabolism
ofhalo-olefins. I think the conference also has illus-
trated that we have a lot yet to learn.
I want to thank Dr. Falk and the National Insti-
tute of Environmental Health Sciences for giving
me, all of us, the opportunity to participate in this
very comprehensive updating of the toxicology of
this important class ofchemical compounds. I think
Dr. Falk deserves our highest praise and gratitude
for identifying and bringing together all those who
gave such excellent papers here.
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